Cargando…

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

OBJECTIVE: We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with relapsing-remitting multiple sclerosis (RRMS). Changes in NfL levels were also correlated with relapse and MRI outcomes. METHODS: CSF samples were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuhle, Jens, Disanto, Giulio, Lorscheider, Johannes, Stites, Tracy, Chen, Yu, Dahlke, Frank, Francis, Gordon, Shrinivasan, Anupama, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Kappos, Ludwig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409586/ https://www.ncbi.nlm.nih.gov/pubmed/25809304 http://dx.doi.org/10.1212/WNL.0000000000001491

Ejemplares similares

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis
por: Chalkou, Konstantina, et al.
Publicado: (2021)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
por: Kappos, Ludwig, et al.
Publicado: (2015)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
por: Laiho, Aapo, et al.
Publicado: (2018)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Use of Fingolimod in the Management of Relapsing–Remitting Multiple Sclerosis: Experience from Latin America
por: Correale, Jorge, et al.
Publicado: (2015)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
por: Ordoñez-Boschetti, Laura, et al.
Publicado: (2015)

Exploring the effect of vitamin D(3) supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
por: Rolf, Linda, et al.
Publicado: (2017)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
por: Izquierdo, Guillermo, et al.
Publicado: (2017)

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction?
por: Marrie, Ruth Ann
Publicado: (2017)

Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis
por: Røsjø, Egil, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rido4u7f1rcc79f56uh0ki1vcd